Treatment with a Nitric Oxide-Donating NSAID Alleviates Functional Muscle Ischemia in the Mouse Model of Duchenne Muscular Dystrophy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Thomas, Gail D ^a,b   Ye, Jianfeng ^b   de Nardi, Claudio ^c   Monopoli, Angela ^c   Ongini, Ennio ^c   Victor, Ronald G ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NicOx Research Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLURBIPROFEN 4 NITROXYBUTYL ESTER; NITRIC OXIDE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DUCHENNE MUSCULAR DYSTROPHY; FEMORAL ARTERY; FOOD INTAKE; HINDLIMB; MALE; MEAN ARTERIAL PRESSURE; MOUSE; MUSCLE BLOOD FLOW; MUSCLE CONTRACTION; MUSCLE ISCHEMIA; NONHUMAN; VASCULAR CONDUCTANCE; VASOCONSTRICTION; WEIGHT GAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMECHANICS; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; FLURBIPROFEN; HEMODYNAMICS; HINDLIMB; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; NITRIC OXIDE DONORS; NOREPINEPHRINE; TIME FACTORS; VASOCONSTRICTION; WEIGHT GAIN;

GLYCINE MAX; MUS;

EID: 84868354425     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049350     Document Type: Article

References (55)

1. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517.
2. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, et al. (1986) Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323: 646-650.
3. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177-189.
4. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
5. Blake DJ, Weir A, Newey SE, Davies KE, (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82: 291-329.
6. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL, (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90: 3710-3714.
7. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS, (1995) Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82: 743-752.
8. Chang WJ, Iannaccone ST, Lau KS, Masters BSS, McCabe TJ, et al. (1996) Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 93: 9142-9147.
9. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, et al. (2009) Dystrophins carrying spectrin-like repeats 16/17 anchor nNOS to the sarcolemma and enhance exercise performance. J Clin Invest 119: 624-635.
10. Sander M, Chavoshan B, Harris SA, Iannoccone ST, Stull JT, et al. (2000) Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 97: 13818-13823.
11. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, et al. (1998) Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 95: 15090-15095.
12. Thomas GD, Shaul PW, Yuhanna IS, Froehner SC, Adams ME, (2003) Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ Res 92: 554-560.
13. Chavoshan B, Sander M, Sybert TE, Hansen J, Victor RG, et al. (2002) Nitric oxide-dependent modulation of sympathetic neural control of oxygenation in exercising human skeletal muscle. J Physiol 540: 377-386.
14. Thomas GD, Victor RG, (1998) Nitric oxide mediates contraction-induced attenuation of sympathetic vasoconstriction in rat skeletal muscle. J Physiol 506: 817-826.
15. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, et al. (2007) Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE 2: e806.
16. Rando TA, (2001) Role of nitric oxide in the pathogenesis of muscular dystrophies: a "two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech 55: 223-235.
17. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, et al. (2007) Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A 104: 264-269.
18. Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, et al. (2004) A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol 150: 10-19.
19. Munzel T, Daiber A, Gori T, (2011) Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123: 2132-2144.
20. D'Angelo MG, Gandossini S, Martinelli Boneschi F, Sciorati C, Bonato S, et al. (2012) Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res 65: 472-479.
21. Sciorati C, Miglietta D, Buono R, Pisa V, Cattaneo D, et al. (2011) A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res 64: 210-217.
22. Keeble JE, Moore PK, (2002) Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 137: 295-310.
23. Wallace JL, Viappiani S, Bolla M, (2009) Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci 30: 112-117.
24. Muscara MN, McKnight W, Lovren F, Triggle CR, Cirino G, et al. (2000) Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol 279: H528-H535.
25. Bertrand V, Guimbaud R, Sogni P, Lamrani A, Mauprivez C, et al. (1998) Role of tumour necrosis factor-alpha and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity. Eur J Pharmacol 356: 245-253.
26. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M, (2009) Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 104: 840-845.
27. Maffia P, Ianaro A, Sorrentino R, Lippolis L, Maiello FM, et al. (2002) Beneficial effects of NO-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis. Arterioscler Thromb Vasc Biol 22: 263-267.
28. Aldini G, Carini M, Orioli M, Facino RM, Wenk GL, (2002) Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: a LC-MS study. Life Sci 71: 1487-1500.
29. Zacharowski P, Zacharowski K, Donnellan C, Johnston A, Vojnovic I, et al. (2004) The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. Clin Pharmacol Ther 76: 350-358.
30. Fadel PJ, Farias III M, Gallagher KM, Wang Z, Thomas GD, (2012) Oxidative stress and enhanced sympathetic vasoconstriction in contracting muscles of nitrate-tolerant rats and humans. J Physiol 590: 395-407.
31. Govoni M, Casagrande S, Maucci R, Chiroli V, Tocchetti P, (2006) In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: comparison with glyceryl trinitrate. J Pharmacol Exp Ther 317: 752-761.
32. Hansen J, Thomas GD, Harris SA, Parsons WJ, Victor RG, (1996) Differential sympathetic neural control of oxygenation in resting and exercising human skeletal muscle. J Clin Invest 98: 584-596.
33. Adami A, Cuzzolin L, Minuz P, Crivellente F, Lechi A, et al. (1996) Vasodilating properties of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on rat aortic rings. Pharmacol Res 33: 239-244.
34. Keeble J, Al-Swayeh OA, Moore PK, (2001) Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol 133: 1023-1028.
35. Carini M, Aldini G, Stefani R, Orioli M, Facino RM, (2001) Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J Pharm Biomed Anal 26: 509-518.
36. Prosperi C, Scali C, Pepeu G, Casamenti F, (2001) NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn J Pharmacol 86: 230-235.
37. Lundberg JO, Weitzberg E, Gladwin MT, (2008) The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7: 156-167.
38. van Faassen EE, Bahrami S, Feelisch M, Hogg N, Kelm M, et al. (2009) Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev 29: 683-741.
39. Zweier JL, Li H, Samouilov A, Liu X, (2010) Mechanisms of nitrite reduction to nitric oxide in the heart and vessel wall. Nitric Oxide 22: 83-90.
40. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, et al. (2010) MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 12: 341-351.
41. Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, et al. (2008) HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A 105: 19183-19187.
42. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, et al. (2009) Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med 15: 325-330.
43. Li D, Yue Y, Lai Y, Hakim CH, Duan D, (2011) Nitrosative stress elicited by nNOSmicro delocalization inhibits muscle force in dystrophin-null mice. J Pathol 223: 88-98.
44. Suzuki N, Motohashi N, Uezumi A, Fukada S, Yoshimura T, et al. (2007) NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 117: 2468-2476.
45. Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ, (2009) Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 36: 1290-1297.
46. Adamo CM, Dai DF, Percival JM, Minami E, Willis MS, et al. (2010) Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 107: 19079-19083.
47. Archer JD, Vargas CC, Anderson JE, (2006) Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 20: 738-740.
48. Barton ER, Morris L, Kawana M, Bish LT, Toursel T, (2005) Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 32: 751-760.
49. Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, et al. (2010) Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS ONE 5: e11220.
50. Hnia K, Gayraud J, Hugon G, Ramonatxo M, De La Porte S, et al. (2008) L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 172: 1509-1519.
51. Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, et al. (2008) Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A 105: 7028-7033.
52. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, et al. (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456: 511-515.
53. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, et al. (2012) Sildenafil Reduces Respiratory Muscle Weakness and Fibrosis in the mdx Mouse Model of Duchenne Muscular Dystrophy. J Pathol 228: 77-87.
54. Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, et al. (2005) L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 20: 123-130.
55. Finanger Hedderick EL, Simmers JL, Soleimani A, Andres-Mateos E, Marx R, et al. (2011) Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders. Neurology 76: 960-967.